Akari Therapeutics (AKTX) Competitors $1.18 +0.07 (+6.11%) As of 04/15/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKTX vs. OGI, ADCT, KOD, TNXP, CGEN, NKTX, CYBN, PROC, EPRX, and TLSAShould you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Organigram (OGI), ADC Therapeutics (ADCT), Kodiak Sciences (KOD), Tonix Pharmaceuticals (TNXP), Compugen (CGEN), Nkarta (NKTX), Cybin (CYBN), Procaps Group (PROC), Eupraxia Pharmaceuticals (EPRX), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry. Akari Therapeutics vs. Organigram ADC Therapeutics Kodiak Sciences Tonix Pharmaceuticals Compugen Nkarta Cybin Procaps Group Eupraxia Pharmaceuticals Tiziana Life Sciences Akari Therapeutics (NASDAQ:AKTX) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings. Which has higher valuation and earnings, AKTX or OGI? Akari Therapeutics has higher earnings, but lower revenue than Organigram. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkari TherapeuticsN/AN/A-$10.01MN/AN/AOrganigram$166.12M0.79-$33.39M-$0.38-2.74 Does the media prefer AKTX or OGI? In the previous week, Organigram had 2 more articles in the media than Akari Therapeutics. MarketBeat recorded 3 mentions for Organigram and 1 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 1.89 beat Organigram's score of 1.18 indicating that Akari Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Akari Therapeutics Very Positive Organigram Positive Does the MarketBeat Community favor AKTX or OGI? Akari Therapeutics received 64 more outperform votes than Organigram when rated by MarketBeat users. However, 70.71% of users gave Organigram an outperform vote while only 50.00% of users gave Akari Therapeutics an outperform vote. CompanyUnderperformOutperformAkari TherapeuticsOutperform Votes26250.00% Underperform Votes26250.00% OrganigramOutperform Votes19870.71% Underperform Votes8229.29% Is AKTX or OGI more profitable? Akari Therapeutics has a net margin of 0.00% compared to Organigram's net margin of -31.69%. Akari Therapeutics' return on equity of 0.00% beat Organigram's return on equity.Company Net Margins Return on Equity Return on Assets Akari TherapeuticsN/A N/A N/A Organigram -31.69%-8.59%-6.54% Which has more volatility & risk, AKTX or OGI? Akari Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Organigram has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Do analysts prefer AKTX or OGI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Organigram 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in AKTX or OGI? 5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Organigram shares are owned by institutional investors. 38.9% of Akari Therapeutics shares are owned by insiders. Comparatively, 0.1% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryAkari Therapeutics and Organigram tied by winning 7 of the 14 factors compared between the two stocks. Remove Ads Get Akari Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKTX vs. The Competition Export to ExcelMetricAkari TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.88M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E RatioN/A6.7921.7317.81Price / SalesN/A225.96379.2094.61Price / CashN/A65.6738.1534.64Price / Book-39.965.866.464.00Net Income-$10.01M$141.86M$3.20B$247.23M7 Day Performance0.75%4.50%2.85%1.45%1 Month Performance11.00%-12.65%-8.55%-6.24%1 Year Performance3.34%-11.06%10.46%0.60% Akari Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKTXAkari TherapeuticsN/A$1.20+7.7%N/A-0.1%$31.88MN/A0.009Positive NewsGap UpOGIOrganigram0.6704 of 5 stars$0.92-2.7%N/A-44.7%$116.74M$166.12M-2.43860Positive NewsADCTADC Therapeutics2.131 of 5 stars$1.17-1.3%$7.75+565.2%-72.6%$115.43M$70.84M-0.49310Gap DownKODKodiak Sciences3.6268 of 5 stars$2.18-7.2%$9.00+312.8%-40.3%$114.99MN/A-0.6090Short Interest ↑Gap DownTNXPTonix Pharmaceuticals2.4472 of 5 stars$17.80+13.8%$585.00+3,186.5%-96.4%$114.54M$10.09M0.0050CGENCompugen1.8915 of 5 stars$1.26-3.8%$4.00+217.5%-29.6%$112.44M$27.86M63.0070NKTXNkarta2.8405 of 5 stars$1.56-4.3%$14.86+852.4%-80.4%$110.69MN/A-0.83140Short Interest ↓Gap UpCYBNCybin1.5261 of 5 stars$5.15-9.5%$86.00+1,569.9%N/A$110.61MN/A-1.1850PROCProcaps GroupN/A$0.95-40.3%N/A-63.5%$107.18M$409.92M0.004,900Positive NewsGap DownHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.3515 of 5 stars$2.97+1.7%$10.50+253.5%+23.9%$105.87MN/A-4.1229Gap UpTLSATiziana Life Sciences1.1048 of 5 stars$0.90-4.6%N/A+62.0%$105.19MN/A0.008Positive News Remove Ads Related Companies and Tools Related Companies Organigram Competitors ADC Therapeutics Competitors Kodiak Sciences Competitors Tonix Pharmaceuticals Competitors Compugen Competitors Nkarta Competitors Cybin Competitors Procaps Group Competitors Eupraxia Pharmaceuticals Competitors Tiziana Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKTX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics, Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKTX Stock Free AKTX Stock Alerts